Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact

One reason why some patients experience recurrent disease after a curative-intent treatment might be the persistence of residual tumor cells, called minimal residual disease (MRD). MRD cannot be identified by standard radiological exams or clinical evaluation. Tumor-specific alterations found in the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Natasha Honoré, Rachel Galot, Cédric van Marcke, Nisha Limaye, Jean-Pascal Machiels
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	liquid biopsy minimal residual disease ctDNA Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/e001f60a26ed43499e1d6ba8b3142e08
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e001f60a26ed43499e1d6ba8b3142e08
record_format	dspace
spelling	oai:doaj.org-article:e001f60a26ed43499e1d6ba8b3142e082021-11-11T15:29:06ZLiquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact10.3390/cancers132153642072-6694https://doaj.org/article/e001f60a26ed43499e1d6ba8b3142e082021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5364https://doaj.org/toc/2072-6694One reason why some patients experience recurrent disease after a curative-intent treatment might be the persistence of residual tumor cells, called minimal residual disease (MRD). MRD cannot be identified by standard radiological exams or clinical evaluation. Tumor-specific alterations found in the blood indirectly diagnose the presence of MRD. Liquid biopsies thus have the potential to detect MRD, allowing, among other things, the detection of circulating tumor DNA (ctDNA), circulating tumor cells (CTC), or tumor-specific microRNA. Although liquid biopsy is increasingly studied, several technical issues still limit its clinical applicability: low sensitivity, poor standardization or reproducibility, and lack of randomized trials demonstrating its clinical benefit. Being able to detect MRD could give clinicians a more comprehensive view of the risk of relapse of their patients and could select patients requiring treatment escalation with the goal of improving cancer survival. In this review, we are discussing the different methodologies used and investigated to detect MRD in solid cancers, their respective potentials and issues, and the clinical impacts that MRD detection will have on the management of cancer patients.Natasha HonoréRachel GalotCédric van MarckeNisha LimayeJean-Pascal MachielsMDPI AGarticleliquid biopsyminimal residual diseasectDNANeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5364, p 5364 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	liquid biopsy minimal residual disease ctDNA Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	liquid biopsy minimal residual disease ctDNA Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Natasha Honoré Rachel Galot Cédric van Marcke Nisha Limaye Jean-Pascal Machiels Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact
description	One reason why some patients experience recurrent disease after a curative-intent treatment might be the persistence of residual tumor cells, called minimal residual disease (MRD). MRD cannot be identified by standard radiological exams or clinical evaluation. Tumor-specific alterations found in the blood indirectly diagnose the presence of MRD. Liquid biopsies thus have the potential to detect MRD, allowing, among other things, the detection of circulating tumor DNA (ctDNA), circulating tumor cells (CTC), or tumor-specific microRNA. Although liquid biopsy is increasingly studied, several technical issues still limit its clinical applicability: low sensitivity, poor standardization or reproducibility, and lack of randomized trials demonstrating its clinical benefit. Being able to detect MRD could give clinicians a more comprehensive view of the risk of relapse of their patients and could select patients requiring treatment escalation with the goal of improving cancer survival. In this review, we are discussing the different methodologies used and investigated to detect MRD in solid cancers, their respective potentials and issues, and the clinical impacts that MRD detection will have on the management of cancer patients.
format	article
author	Natasha Honoré Rachel Galot Cédric van Marcke Nisha Limaye Jean-Pascal Machiels
author_facet	Natasha Honoré Rachel Galot Cédric van Marcke Nisha Limaye Jean-Pascal Machiels
author_sort	Natasha Honoré
title	Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact
title_short	Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact
title_full	Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact
title_fullStr	Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact
title_full_unstemmed	Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact
title_sort	liquid biopsy to detect minimal residual disease: methodology and impact
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/e001f60a26ed43499e1d6ba8b3142e08
work_keys_str_mv	AT natashahonore liquidbiopsytodetectminimalresidualdiseasemethodologyandimpact AT rachelgalot liquidbiopsytodetectminimalresidualdiseasemethodologyandimpact AT cedricvanmarcke liquidbiopsytodetectminimalresidualdiseasemethodologyandimpact AT nishalimaye liquidbiopsytodetectminimalresidualdiseasemethodologyandimpact AT jeanpascalmachiels liquidbiopsytodetectminimalresidualdiseasemethodologyandimpact
_version_	1718435274872061952

Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact

Ejemplares similares